Correction: Cytokinetics Announces Baseline Characteristics from GALACTIC-HF at ACC.20/WCC Virtual

Top-line Results for GALACTIC-HF Expected in Q4 2020 SOUTH SAN FRANCISCO, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- In the press release published at 7:30 AM ET on March 30, 2020, due to a newswire service error, the quotation from John Teerlink, M.D., was omitted. The corrected press release in its entirety follows. Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that patient baseline characteristics and demographics from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 event driven cardiovascular outcomes clinical trial of omecamtiv mecarbil, were published during the American College of Cardiology 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC).   Overall (N=8,256) Inpatient (N=2,083) Outpatient (N=6,173) Time from most recent HF hospitalization/ ED visit (months), median (Q1-Q3) 2 (1-5) - 3 (2-6) Age (years), mean (SD) 65 (11) 65 (11) 64 (11) Male, % 79 80 78 White, % 78 82 76 LVEF (%), mean (SD) 27 (6) 27 (6) 27 (6) NYHA Class II/III/IV, % 53/ 44/ 3 37/ 57/ 6 59/ 39/ 2 NT-proBNP (pg/mL), median (Q1-Q3) 1998 (990-4078) 2509 (1240-5133) 1884 (923-3772) Ischemic Heart Disease Etiology, % 55 56 54 KCCQ Total Symptom Score, mean (SD) 66 (25) 53 (25) 71 (23) Atrial Fibrillation or Flutter History, % 42 48 40 Chronic Kidney Disease, % 36 39 35 eGFR (mL/min/1.73m2), median (Q1-Q3) 59 (44-74) 54 (41-70) 60 (45-75) SBP (mmHg), mean (SD) 117 (15) 114 (14) 117 (16) ACEi, ARB or ARNi, % 87 83 88   ARNi (ENTRESTO®) % 19 14 19 Beta Blocker, % 94 93 95 MRA, % 77 81 76 Diuretics other than MRAs, % 90 92 89 Digitalis Glycosides, % 17 17 17 SGLT2 Inhibitors, % 3 3 3

The release as fetched from its publisher. cytokinetics.com ↗